Two snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing

BACKGROUND: Snakebite is a major public health concern in Eswatini, where treatment relies upon one antivenom—SAIMR Polyvalent. Although effective in treating snakebite, SAIMR Polyvalent is difficult to source outside its manufacturing country (South Africa) and is dauntingly expensive. We compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzies, Stefanie K., Litschka-Koen, Thea, Edge, Rebecca J., Alsolaiss, Jaffer, Crittenden, Edouard, Hall, Steven R., Westhorpe, Adam, Thomas, Brent, Murray, James, Shongwe, Nondusimo, Padidar, Sara, Lalloo, David G., Casewell, Nicholas R., Pons, Jonathan, Harrison, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529146/
https://www.ncbi.nlm.nih.gov/pubmed/36108067
http://dx.doi.org/10.1371/journal.pntd.0010496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529146/
https://www.ncbi.nlm.nih.gov/pubmed/36108067
http://dx.doi.org/10.1371/journal.pntd.0010496

Ejemplares similares